USC Launches First-in-Human Trial of Cartilage-Protecting Knee Injection

Knee osteoarthritis is one of the most common and stubbornly untreatable conditions in modern medicine, affecting tens of millions of people who are told, year after year, that the best anyone can offer is pain relief while the joint continues to wear away. Now, clinicians and scientists at Keck Medicine of USC have opened a clinical trial that aims to test whether that long-standing limitation can finally be overcome. The study is evaluating an investigational therapy called CX-011, delivered as a single injection directly into the knee joint, with the goal of assessing its safety and tolerability and gathering early evidence about whether it can slow or prevent the deterioration of cartilage in people living with the disease. The trial is registered on ClinicalTrials.gov, and Keck Medicine is the sole site conducting the study, a detail that underscores how closely the research is tied to the institution where the underlying science was born.

The scale of the problem the trial addresses is difficult to overstate. Approximately 33 million Americans live with osteoarthritis, the most common form of arthritis and a progressive disease in which the cartilage that cushions the joints gradually breaks down. Cartilage is the smooth, resilient tissue that allows bones to glide over one another with almost frictionless ease, and once it is lost, the body has very limited capacity to rebuild it. As the cushioning thins, patients experience chronic pain, stiffness and reduced mobility, and everyday activities such as walking, climbing stairs or rising from a chair become increasingly difficult. The disease does not merely affect comfort; it reshapes how people live, work and remain independent as they age.

Current treatment options reflect the limits of the field. Physical therapy, weight management, oral anti-inflammatory medications and injections such as corticosteroids or hyaluronic acid can ease symptoms for a time, but none of them stop the underlying disease from progressing. For many patients, the endpoint of this trajectory is joint replacement surgery, a major operation that replaces the damaged joint with a prosthetic implant. While replacement surgery is often successful, it is invasive, expensive and carries the risks inherent to any major procedure, and artificial joints have their own lifespan and limitations. This is the gap that the USC team hopes to close: a therapy that moves beyond symptom management and actually preserves the health of the joint itself.

For decades, physicians have helped patients manage the pain of osteoarthritis but have never been able to stop the disease from progressing, as Jay R. Lieberman, MD, chief of USC Orthopaedic Surgery with Keck Medicine and chair of the Department of Orthopaedic Surgery with the Keck School of Medicine of USC, who is leading the clinical trial, has observed. He has expressed the hope that the field can one day move beyond symptom management and toward preserving joint health for patients. That ambition places the CX-011 trial in a category of research that many rheumatologists and orthopaedic scientists consider the holy grail of the field: a disease-modifying osteoarthritis drug, something that has eluded the pharmaceutical industry despite decades of effort and billions of dollars in investment.

The scientific foundation of CX-011 lies in work carried out in the Department of Orthopaedic Surgery at the Keck School of Medicine, where Denis Evseenko, MD, PhD, vice chair for research in orthopaedic surgery and a professor of orthopaedic surgery, stem cell research and regenerative medicine, led the studies that produced the therapy. His team focused on a series of molecular signals involving GP130, an immune system receptor that tells cells how to respond to inflammation. GP130 is not a villain in the body’s biology; it supports normal immune, cardiovascular and stem cell functions, and it is essential to healthy physiology. The problem arises in osteoarthritis, where immune system signals routed through this pathway can become overactive and contribute to further cartilage damage, creating a self-reinforcing cycle of deterioration in which inflammation begets tissue loss, and tissue loss begets more inflammation.

CX-011 was designed with that nuance in mind. Rather than shutting GP130 down entirely, which could disrupt the many healthy processes that depend on it, the therapy was engineered to interrupt the inflammation-related signaling that drives cartilage destruction while leaving the receptor’s beneficial functions intact. This selective modulation is what distinguishes the approach from blunt immunosuppression. In animal models of osteoarthritis, Evseenko’s team observed signs of reduced joint pain, improved joint structure and function, cartilage regeneration and tissue healing after administering CX-011. Those preclinical findings, encouraging as they were, could only suggest what might be possible in humans, and they provided the rationale for moving the therapy into clinical testing.

The trial now underway at Keck Medicine is a randomized, double-blind, early-phase study, a design in which participants are assigned to different treatment groups and neither the participants nor the researchers directly involved know who receives which assignment. This structure is considered the gold standard for minimizing bias in clinical research. The primary goal of the trial is to evaluate the safety and tolerability of the investigational injection, which is the essential first question any new therapy must answer before it can be considered for wider use. In addition to safety, the researchers will use standardized questionnaires and MRI scans to collect information about participants’ pain, physical function and cartilage health over the course of the trial. The use of MRI is particularly significant, because it allows investigators to visualize cartilage directly and track structural changes in the joint rather than relying solely on how patients report feeling.

The journey from laboratory discovery to a clinical trial is rarely straightforward, and the USC team credits a key institutional bridge for making it happen. The USC Office of Research and Innovation, through the Alfred E. Mann Institute, was instrumental in bringing Evseenko’s preclinical findings toward a potential therapy. The institute helps develop promising biomedical discoveries for clinical use by providing venture funding, industry connections and strategic guidance, including support for researchers who form and grow companies to develop new technologies and treatments for patients. This model of translational infrastructure addresses one of the most persistent bottlenecks in academic medicine: promising discoveries that stall in the laboratory because the path to clinical validation requires capital, regulatory expertise and commercial partnerships that universities alone often cannot supply.

Lieberman has emphasized the value of that integrated environment, noting that as an academic health system, USC brings scientists and physicians together to shape research around the needs of patients, and that this collaboration, combined with the resources needed to move discoveries beyond the laboratory, allows the institution to rigorously evaluate emerging approaches that may expand patients’ treatment options. The trial is funded by CarthroniX Inc., the developer of CX-011. In keeping with transparency standards for clinical research, the announcement discloses that Evseenko is a co-founder and major shareholder of CarthroniX Inc. and its parent company, Innata Bio, and that USC’s Alfred E. Mann Institute is an investor in Innata Bio, with USC also holding a financial interest in CarthroniX Inc. Such disclosures are a routine and important part of how academic-industry partnerships are reported, allowing readers and regulators to weigh the research with full knowledge of the financial relationships involved.

For the millions of people whose knees are slowly wearing out, the significance of this trial lies in what it represents: a serious, rigorously designed attempt to test whether a single injection can do what no approved therapy currently can, namely protect cartilage from the destructive course of osteoarthritis. It is important to temper expectations appropriately, as early-phase trials are designed first and foremost to establish safety, and promising results in animal models do not guarantee success in humans. The investigators themselves frame the study as an evaluation of safety and tolerability, with cartilage outcomes collected as exploratory measures. Still, if CX-011 proves safe and shows even early signals of preserving joint structure, it would mark a meaningful step toward a long-sought shift in osteoarthritis care, from managing decline to preventing it, and would validate a strategy of fine-tuning inflammatory signaling rather than suppressing it outright. The results of this trial will be watched closely by clinicians, researchers and patients alike, because the answer it seeks, whether a joint can be preserved rather than replaced, would change the conversation for an entire generation of people living with the disease.

Subject of Research: A first-in-human clinical trial evaluating the safety and cartilage-protective potential of the investigational injection CX-011 for knee osteoarthritis.

Article Title: Clinical trial evaluates investigational injection for knee osteoarthritis

Article References: Clinical trial evaluates investigational injection for knee osteoarthritis. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: knee osteoarthritis, CX-011, clinical trial, cartilage, GP130, inflammation, Keck Medicine of USC, Jay Lieberman, Denis Evseenko, regenerative medicine, joint replacement, MRI